Skip to main content
Michael Fried, MD, Gastroenterology, Chapel Hill, NC

MichaelWFriedMDFAASLD

Gastroenterology Chapel Hill, NC

Hepatology & Liver Transplantation

Professor of Medicine, University of North Carolina School of Medicine

Dr. Fried is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Fried's full profile

Already have an account?

  • Office

    University of North Carolina
    101 Manning Drive
    Chapel Hill, NC 27514
    Phone+1 919-843-6386

Summary

  • Michael W. Fried, MD, FAASLD

    is Professor of Medicine and Director of Hepatology at the University of North Carolina (UNC) at Chapel Hill. Dr. Fried served as President of the American Association for the Study of Liver Diseases (AASLD) in 2019. He completed his internship and residency in internal medicine at the State University of New York (SUNY) Health Science Center at Syracuse, where he also completed a fellowship in gastroenterology.

    From 1990 to 1993, while serving as Medical Staff Fellow in the Liver Diseases Section at the National Institutes of Health (NIH) in Bethesda, Maryland, Dr. Fried performed clinical and laboratory studies of viral hepatitis. During his tenure at UNC, he has been the principal investigator on numerous clinical trials of antiviral agents for chronic hepatitis B and hepatitis C. Dr. Fried has been awarded continuous NIH extramural funding for over 20 years as principal investigator on several NIH cooperative clinical trials and he currently serves as the co-chair of the Hepatitis B Research Network (NIDDK). Most recently, Dr. Fried is co-principal investigator of the HCV-TARGET international network studying HCV therapies used in usual clinical practice and co-PI of PRIORITIZE, a pragmatic clinical trial of HCV therapeutics.

    Dr. Fried is the primary author or co-author on over 200 original publications, reviews, and book chapters concentrated in the field of viral hepatitis. He was inducted into the American Society of Clinical Investigation (ASCI), an honor society for clinical investigators.

Education & Training

  • Clinical Center at the National Institutes of Health
    Clinical Center at the National Institutes of HealthFellowship, Liver Diseases, 1990 - 1993
  • SUNY Upstate Medical University
    SUNY Upstate Medical UniversityFellowship, Gastroenterology, 1987 - 1989
  • SUNY Upstate Medical University
    SUNY Upstate Medical UniversityResidency, Internal Medicine, 1984 - 1987
  • Tel Aviv University Sackler
    Tel Aviv University SacklerClass of 1984

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1984 - Present
  • NC State Medical License
    NC State Medical License 1998 - 2024
  • GA State Medical License
    GA State Medical License 1993 - 1999
  • MD State Medical License
    MD State Medical License 1989 - 1994
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

  • President American Association for the Study of Liver Diseases (AASLD), 2019
  • President-Elect American Association for the Study of Liver Diseases (AASLD), 2018
  • America's Top Doctors Castle Connolly, 2012-2018
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Comprehensive Assessment of Patient Reported Symptom Burden, Medical Comorbidities, and Functional Well Being in Patients Initiating Direct Acting Antiviral Therapy ...  
    Souvik Sarkar, Michael W. Fried, Richard K. Sterling, Paul W. Stewart, Nancy Reau, Joseph K. Lim, David R. Nelson, Marina Serper, PLoS One

Lectures

  • Hepatitis C Management: State of the Art 2013 
    Hepatitis C Management, New York, New York - 5/9/2013

Press Mentions

  • Target RWE Announces the Launch of Engage™ - an Innovative, Digital Patient-Centric Engagement Platform
    Target RWE Announces the Launch of Engage™ - an Innovative, Digital Patient-Centric Engagement PlatformAugust 21st, 2024
  • World’s Largest Liver Disease-Focused Registry Surpasses 400,000 Patient Enrollment Milestone
    World’s Largest Liver Disease-Focused Registry Surpasses 400,000 Patient Enrollment MilestoneJune 4th, 2024
  • New Partnership Launches Carolina Hepatitis Academic Mentorship Program
    New Partnership Launches Carolina Hepatitis Academic Mentorship ProgramMarch 14th, 2017

Grant Support

  • Mentoring Junior Faculty: Viral Hepatitis Clinical ResearchNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2012
  • The North Carolina Hepatitis Beta Clinical Research NetworkNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2011
  • Division Of Digestive Diseases Serum And Tissue BankNational Center For Research Resources2008
  • A Phase I/II Randomized, Placebo Controlled Trial Of Silymarin For Hepatitis CNational Center For Complementary &Alternative Medicine2006–2008
  • Mentoring Junior Faculty: Hepatitis C Clinical ResearchNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2008
  • Pegasys PLUS Amantadine And Pegasys PLUS Amantadine PLUS RibavirinNational Center For Research Resources2006
  • Virahep-C: A Study Of Antiviral Resistance In AFR Amer/Caucasian-Hep CNational Center For Research Resources2005–2006
  • Interferon Resistance In African-AmericansNational Center For Research Resources2004–2005
  • Hepatitis C Antiviral Resistance In African AmericansNational Institute Of Diabetes And Digestive And Kidney Diseases2001–2005
  • Virahep-C: A Study Of Antiviral Resistance In Afr. Amer./Caucasian-Hep CNational Center For Research Resources2004
  • Pilot--Alcohol And Hepatitis C Host Response And Disease ActivityNational Institute On Alcohol Abuse And Alcoholism2003–2004
  • Hepatitis C In Clinically Discordant Hemophilic SiblingsNational Heart, Lung, And Blood Institute1999–2002
  • Famciclovir For Chronic Hepatitis BNational Center For Research Resources1997
  • Chronic Hepatitis C Infection In Urban African AmericansNational Institute Of Allergy And Infectious Diseases1996

Committees

  • Board Liason, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD) 2016 - Present

Professional Memberships